Anjaneya Chimalakonda
Overview
Explore the profile of Anjaneya Chimalakonda including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
345
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Jing S, Lin Y, Dockens R, Marchisin D, He B, Girgis I, et al.
Dermatol Ther (Heidelb)
. 2023 Nov;
13(12):3153-3164.
PMID: 37981596
Introduction: Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, blocks cytokine signaling involved in psoriasis pathogenesis. This ethnic-bridging study evaluated deucravacitinib pharmacokinetics, tolerability, and safety in healthy Chinese subjects....
2.
Absolute and Relative Bioavailability of Oral Solid Dosage Formulations of Deucravacitinib in Humans
Chimalakonda A, Li W, Marchisin D, He B, Singhal S, Deshpande P, et al.
Clin Pharmacol Drug Dev
. 2023 Aug;
12(10):956-965.
PMID: 37587797
Deucravacitinib is an oral, selective, allosteric inhibitor of tyrosine kinase 2, an intracellular signaling kinase involved in the pathogenesis of immune-mediated inflammatory diseases. The absolute and relative bioavailability (BA) were...
3.
Chimalakonda A, Singhal S, Darbenzio R, Dockens R, Marchisin D, Banerjee S, et al.
Clin Pharmacol Drug Dev
. 2022 Feb;
11(4):442-453.
PMID: 35182043
Deucravacitinib is a novel, oral, selective inhibitor of the intracellular signaling kinase tyrosine kinase 2. This phase 1, randomized, partially double-blind, 4-period crossover study in healthy adults was conducted to...
4.
Chimalakonda A, Burke J, Cheng L, Catlett I, Tagen M, Zhao Q, et al.
Dermatol Ther (Heidelb)
. 2021 Sep;
11(5):1763-1776.
PMID: 34471993
Introduction: Deucravacitinib, a novel, oral, selective inhibitor of tyrosine kinase 2 (TYK2) signaling, acts via an allosteric mechanism by binding to the enzyme's regulatory domain instead of the catalytic domain....
5.
Sharda N, Khandelwal P, Zhang L, Caceres-Cortes J, Marathe P, Chimalakonda A
Eur J Pharm Sci
. 2021 Jul;
165:105928.
PMID: 34265405
Conjugation with polyethylene glycol (PEG), PEGylation, has been considered a useful tool to improve drug-like properties of novel small molecules and biologics in drug discovery. PEG40 or 40 kDa PEG...
6.
Liu C, Lin J, Langevine C, Smith D, Li J, Tokarski J, et al.
J Med Chem
. 2020 Dec;
64(1):677-694.
PMID: 33370104
A search for structurally diversified Tyk2 JH2 ligands from (BMS-986165), a pyridazine carboxamide-derived Tyk2 JH2 ligand as a clinical Tyk2 inhibitor currently in late development for the treatment of psoriasis,...
7.
Nair S, Kumar S, Paidi V, Sistla R, Kantheti D, Polimera S, et al.
ACS Med Chem Lett
. 2020 Jul;
11(7):1402-1409.
PMID: 32676146
IRAK4 is an attractive therapeutic target for the treatment of inflammatory conditions. Structure guided optimization of a nicotinamide series of inhibitors has been expanded to explore the IRAK4 front pocket....
8.
Burke J, Cheng L, Gillooly K, Strnad J, Zupa-Fernandez A, Catlett I, et al.
Sci Transl Med
. 2019 Jul;
11(502).
PMID: 31341059
TYK2 is a nonreceptor tyrosine kinase involved in adaptive and innate immune responses. A deactivating coding variant has previously been shown to prevent receptor-stimulated activation of this kinase and provides...
9.
Wrobleski S, Moslin R, Lin S, Zhang Y, Spergel S, Kempson J, et al.
J Med Chem
. 2019 Jul;
62(20):8973-8995.
PMID: 31318208
Small molecule JAK inhibitors have emerged as a major therapeutic advancement in treating autoimmune diseases. The discovery of isoform selective JAK inhibitors that traditionally target the catalytically active site of...
10.
Khandelwal P, Zhang L, Chimalakonda A, Caceres-Cortes J, Huang C, Marathe P, et al.
J Pharm Biomed Anal
. 2019 Apr;
171:30-34.
PMID: 30959317
Conjugation of macromolecular drugs to polyethylene glycol (PEG) improves their therapeutic potential by reducing their rate of degradation, thereby extending the drugs half life. As a substantial component of the...